Last reviewed · How we verify
SHEN211 Tablets
At a glance
| Generic name | SHEN211 Tablets |
|---|---|
| Also known as | Test group |
| Sponsor | JKT Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19) (PHASE2)
- The Safety, Tolerability, Pharmacokinetics and Food Effects of SHEN211 Tablet in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHEN211 Tablets CI brief — competitive landscape report
- SHEN211 Tablets updates RSS · CI watch RSS
- JKT Biopharma Co., Ltd. portfolio CI